Loading
Everything OnCo dates to 2001: 85 entries, 16 landmarks, 15 papers, 15 papers listed on people's pages and 13 approvals. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
85 dated entries in OnCo fall in 2001: 16 landmarks, 15 papers, 15 papers listed on people's pages, 13 approvals, 13 companies founded, 6 journals founded, 4 technologies, 2 trials reported and 1 regulatory event.
Of those, 1 to the day and 84 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
B-CLL after fludarabine (MabCampath; authorisation withdrawn 2012)
B-cell chronic lymphocytic leukaemia (single agent)
Skin manifestations of advanced-stage CTCL refractory to at least one systemic treatment
Colorectal, gastric and breast cancer
Anaemia of chronic renal failure; symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy (Aranesp)
Anaemia of chronic kidney disease
Pancreatic cancer: NICE TA25 (8 May 2001), since replaced by the NG85 guideline, which recommends gemcitabine alone for people not well enough for combination chemotherapy (1.9.6)...
Chronic myeloid leukaemia
Treatment and prophylaxis of acute hyperuricaemia in haematological malignancy with high tumour burden (Fasturtec)
Palliative treatment of advanced head and neck squamous cell carcinoma failing prior therapy and unsuitable for radiotherapy, surgery or chemotherapy
Monitoring for recurrence in patients with previously diagnosed bladder cancer
Prevention of skeletal-related events in advanced malignancies involving bone; tumour-induced hypercalcaemia
Hypercalcaemia of malignancy
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
Chronic myeloid leukaemia: first targeted kinase inhibitor, approved in under 3 months
The year reported on trial records, with the headline result the record gives.
Local recurrence at two years 2.4 against 8.2 percent; no survival difference.
Median overall survival 36 vs 27 months (hazard ratio 0.74).
The publication year on key paper records.
Balkwill F, Mantovani A. The Lancet.
Macdonald JS, Smalley SR, Benedetti J, et al. New England Journal of Medicine.
Nicholson RI, Gee JM, Harper ME. European Journal of Cancer.
Dulguerov P, Allal AS, Calcaterra TC. The Lancet Oncology.
Druker BJ, Talpaz M, Resta DJ, et al. New England Journal of Medicine.
Sørlie T, Perou CM, Tibshirani R, et al. Proceedings of the National Academy of Sciences.
Shankaran V, Ikeda H, Bruce AT, et al. Nature.
Hruban RH, Adsay NV, Albores-Saavedra J, et al. American Journal of Surgical Pathology.
Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. New England Journal of Medicine.
Reya T, Morrison SJ, Clarke MF, Weissman IL. Nature.
Slamon DJ, Leyland-Jones B, Shak S, et al. New England Journal of Medicine.
Ladanyi M, Lui MY, Antonescu CR, et al. Oncogene.
Goodwin PJ, Leszcz M, Ennis M, et al. New England Journal of Medicine.
Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. PNAS.
Yarden Y, Sliwkowski MX. Nature Reviews Molecular Cell Biology.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Colloid (mucinous non-cystic) carcinoma of the pancreas
Alveolar soft part sarcoma
Pancreatoblastoma
Uveal melanoma
Renal cell carcinoma
Colorectal cancer. 1,861 patients; two-year local recurrence 2.4 versus 8.2 percent with preoperative radiotherapy, two-year survival identical at 82.0 versus 81.8 percent.
Paget disease of the nipple
KIT exon 11-mutant GIST
Chronic myeloid leukaemia (CML). FDA approval in under three months; IRIS (2003) confirms superiority over interferon-cytarabine.
Leukaemia (all types). The first kinase inhibitor and the model for targeted therapy.
Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)
Chronic myeloid leukaemia, accelerated and blast phase
Pancreatic ductal adenocarcinoma. Eight pathologists had used more than 70 terms for 35 duct lesions; the working group adopted pancreatic intraepithelial neoplasia grades 1 to 3...
Primary mediastinal (thymic) large B-cell lymphoma
Systemic mastocytosis. Valent criteria; imatinib found inactive against D816V.
Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms. CMML, atypical CML and JMML grouped as overlap neoplasms.
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Frankfurt
Lund
Bengaluru
Tokyo
Shenzhen
Charlottesville, VA
Sydney
Cambridge, MA
Dunedin
Boston, Massachusetts
Cambridge, MA
San Francisco, CA
London
The founded year on journal records.
BMC (Springer Nature)
Elsevier
Bentham Science Publishers
Taylor & Francis
American Association for Cancer Research
Springer Nature
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Nature Reviews Cancer
Br J Cancer
Science
Journal of Clinical Oncology
Science
Rozhledy v chirurgii
International Journal of Cancer
New England Journal of Medicine
Nature Immunology
JCO
British Journal of Cancer
Oncogene
JAMA
Journal of the Royal Society of Medicine
New England Journal of Medicine